A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 1, 2014, Pages 68-72

  Thomas, Xavier G ^a   Arthur, Christopher ^b   Delaunay, Jacques ^c   Jones, Mark ^d   Berrak, Erhan ^d   Kantarjian, Hagop M ^e  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d EISAI INC   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Age factors; Chemotherapy; Cytarabine; Dacogen; Treatment outcome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ELECTROCORTICOGRAPHY; GERIATRIC PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SURVIVAL RATE; VERY ELDERLY;

AGE FACTORS; CHEMOTHERAPY; CYTARABINE; DACOGEN; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 84892809398     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.09.007     Document Type: Article

References (18)

1. C. Pautas, F. Merabet, and X. Thomas et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study J Clin Oncol 28 2010 808 814
2. A.K. Burnett, D. Milligan, and A.G. Prentice et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment Cancer 109 2007 1114 1124
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. v.2.2013. National Comprehensive Cancer Network. Available at: www.nccn.org/professionals/physician-gls/pdf/aml.pdf. Accessed July 31, 2013.
4. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia J Clin Oncol 28 2010 562 569
5. A.F. Cashen, G.J. Schiller, and M.R. O'Donnell et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia J Clin Oncol 28 2010 556 561
6. H. Kantarjian, Y. Oki, and G. Garcia-Manero et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 2007 52 57
7. H.M. Kantarjian, H.P. Erba, and D. Claxton et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors J Clin Oncol 28 2010 549 555
8. Dacogen [summary of product characteristics]. European Medicines Agency. Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/002221/human-med-001589.jsp&mid=WC0b01ac058001d124. Accessed July 31, 2013.
9. Dacogen [package insert]. Woodcliff Lake, NJ: Eisai Inc; 2010.
10. H.M. Kantarjian, X.G. Thomas, and A. Dmoszynska et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia J Clin Oncol 30 2012 2670 2677
11. M.L. Slovak, K.J. Kopecky, and P.A. Cassileth et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 2000 4075 4083
12. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
13. A.O. Soriano, H. Yang, and S. Faderl et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 110 2007 2302 2308
14. S. Faderl, F. Ravandi, and X. Huang et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients Cancer 118 2012 4471 4477
15. B. van der Holt, D.A. Breems, and H.B. Beverloo et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial Br J Haematol 136 2007 96 105
16. W. Blum, R. Garzon, and R.B. Klisovic et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine Proc Natl Acad Sci U S A 107 2010 7473 7478
17. L. Shen, H. Kantarjian, and Y. Guo et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes J Clin Oncol 28 2010 605 613
18. R. Claus, D. Pfeifer, and M. Almstedt et al. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia Leuk Res 37 2013 190 196